[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367887-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367887-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-analysis-of-piezo1-a-promising-biomarker-for-diagnosis-prognosis-and-targeted-therapies","Pan-cancer analysis of PIEZO1 - a promising biomarker for diagnosis, prognosis, and targeted therapies","","Pan-cancer analysis evaluates PIEZO1 as a mechanically gated cation channel and examines its utility as a diagnostic, prognostic, and therapeutic biomarker. Using TCGA expression profiles, ROC-based diagnostic testing, and Cox and Kaplan-Meier survival modeling, the study links PIEZO1 with clinical features and outcomes. cBioPortal genomic alterations, R-based pathway enrichment, immune microenvironment and checkpoint correlations, and qRT-PCR/WB validation are integrated with in vitro assays and xenograft experiments.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-analysis-of-piezo1-a-promising-biomarker-for-diagnosis-prognosis-and-targeted-therapies/367887/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-of-piezo1-a-promising-biomarker-for-diagnosis-prognosis-and-targeted-therapies/367887.png","ImageObject",300,407,{"name":42,"@type":43},"Aldword","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How is PIEZO1 evaluated for diagnostic performance?","Question",{"text":63,"@type":64},"Diagnostic value is assessed using ROC curve analysis with primary tumor samples as cases and adjacent normal tissues as controls.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What methods determine the prognostic significance of PIEZO1?",{"text":68,"@type":64},"Prognostic effects are analyzed using Cox regression and Kaplan-Meier survival analyses, followed by clinical correlation testing using non-parametric tests and logistic regression.",{"name":70,"@type":61,"acceptedAnswer":71},"How was PIEZO1’s role functionally validated?",{"text":72,"@type":64},"PIEZO1 expression is quantified using qRT-PCR and Western blotting, and its effects are tested with colony formation and wound healing assays in vitro, while xenograft models evaluate tumor growth in vivo.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367887,1791484023,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Original Research PUBLISHED 04 September 2025 DOI 10.3389/fimmu.2025.1625734  \nOPEN ACCESS  \nEDITED BY  \nLeonardo Mirandola, Kiromic, United States  \nREVIEWED BY  \nKimberly J. Bussey,  \nMidwestern University, United States Liu Xin,  \nTianjin Medical University General Hospital, China  \n*CORRESPONDENCE  \nPengpeng Zhu  \n [Zhupengpeng@xjtu.edu.cn](Zhupengpeng@xjtu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 09 May 2025  \nACCEPTED 22 August 2025  \nPUBLISHED 04 September 2025  \nCITATION  \nWang Q, Yu Y, Liang X, Wan D, Du K and Zhu P (2025) Pan-cancer analysis of PIEZO1:  \na promising biomarker for diagnosis, prognosis, and targeted therapies.  \nFront. Immunol. 16:1625734 .  \ndoi: 10.3389/fimmu.2025.1625734  \nCOPYRIGHT  \n© 2025 Wang, Yu, Liang, Wan, Du and Zhu.  \nThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPan-cancer analysis of PIEZO1: a promising biomarker for diagnosis, prognosis, and targeted therapies  \nQian Wang 1,2†, Yan Yu 3†, Xiao Liang 1, Dan Wan 1, Ke Du 1 and Pengpeng Zhu 1*  \n1 National‐Local Joint Engineering Research Center of Biodiagnosis & Biotherapy, The Second Afﬁliated Hospital, Xi’an Jiaotong University, Xi’an, China, 2The Precision Medical Institute, The Second Afﬁliated Hospital, Xi’an Jiaotong University, Xi’an, China, 3 Department of Pathology, The Afﬁliated Taizhou People’s Hospital of Nanjing Medical University, Taizhou, China  \nIntroduction: Piezo-type mechanosensitive channel component 1 (PIEZO1), a mechanically gated cation channel involved in calcium signaling, has been recognized as a potential oncogene in some cancers . However, its comprehensive pan-cancer role remains unexplored.  \nMethods: This study used The Cancer Genome Atlas (TCGA) data to analyze PIEZO1 expression proﬁles. Diagnostic value was evaluated using Receiver Operating Characteristic (ROC) curve analysis, with primary tumor samples as cases and adjacent normal tissues as controls. Prognostic value was determined through Cox regression and Kaplan-Meier survival analyses. Clinical correlations were detected using non-parametric tests and logistic regression. Genomic alterations were identiﬁed via the cBioPortal database. Functional pathways were analyzed using the R language. The association between PIEZO1 and tumor microenvironment scores (Stromal, Immune, ESTIMATE) or immune checkpoint markers (CD274, CTLA4, LAG3, PDCD1, PDCD1LG2) were analyzed using the R language. Quantitative Real-Time PCR (qRT-PCR) and Western Blotting (WB) were performed to quantify PIEZO1 expression in clinical specimens. Colony formation and wound healing assays assessed PIEZO1 ’s in vitro effects on cancer cells, while xenograft models evaluated its in vivo impact on tumor growth.  \nResults: Our analysis revealed that PIEZO1 has diagnostic and prognostic value across different cancer types. Elevated PIEZO1 expression was associated with advanced tumor grade and stage. Genomic alterations in PIEZO1 were found in 4% of pan-cancer patients. Functional enrichment analyses revealed that PIEZO1-coexpressed genes were signiﬁcantly enriched in ECM-receptor signaling, cell migration, and ion homeostasis. PIEZO1 positively correlated with tumor microenvironment scores and immune checkpoints. Experimental validation conﬁrmed PIEZO1 overexpression in LIHC and its pro-tumorigenic role in vitro/in vivo.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nConclusion: Our ﬁndings indicate that PIEZO1 is a promising marker for the diagnosis, prognosis, and development of targeted pan-cancer therapies.  \nKEYWORDS  \nPIEZO1, pan-c","cbCaigCpMOUd8ATn","https://ap.wps.com/l/cbCaigCpMOUd8ATn","pdf",30917185,22,"English","# Introduction\n## Primary liver cancer background\n## PIEZO1 functions and relevance to cancer\n# Methods\n## TCGA expression analysis\n## Diagnostic and prognostic modeling\n## Genomic alterations and functional enrichment\n## Immune microenvironment and checkpoint association\n## Experimental validation (qRT-PCR, Western blot, assays)\n# Results\n## Diagnostic and prognostic performance across cancers\n## Associations with tumor grade and stage\n## Genomic alterations and pathway enrichment\n## Correlation with microenvironment and immune checkpoints\n## Experimental validation in LIHC","[{\"question\":\"How is PIEZO1 evaluated for diagnostic performance?\",\"answer\":\"Diagnostic value is assessed using ROC curve analysis with primary tumor samples as cases and adjacent normal tissues as controls.\"},{\"question\":\"What methods determine the prognostic significance of PIEZO1?\",\"answer\":\"Prognostic effects are analyzed using Cox regression and Kaplan-Meier survival analyses, followed by clinical correlation testing using non-parametric tests and logistic regression.\"},{\"question\":\"How was PIEZO1’s role functionally validated?\",\"answer\":\"PIEZO1 expression is quantified using qRT-PCR and Western blotting, and its effects are tested with colony formation and wound healing assays in vitro, while xenograft models evaluate tumor growth in vivo.\"}]","Pan-cancer analysis of PIEZO1 - a promising biomarker for diagnosis, prognosis, and targeted therapies | PDF",1790173167,55,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70e2b697d360d478216a92f45d0917f9.webp",983,1389,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58e711b253436d84211bc1d5dbd45803.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11d41208c5e743b4f6cc64ffad6dd9f0.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9edc91650038974e1a9b1dd69500adac.webp",980,1385]